AU2016202235A1 - Antibodies specific for Claudin 6 (CLDN6) - Google Patents
Antibodies specific for Claudin 6 (CLDN6)Info
- Publication number
- AU2016202235A1 AU2016202235A1 AU2016202235A AU2016202235A AU2016202235A1 AU 2016202235 A1 AU2016202235 A1 AU 2016202235A1 AU 2016202235 A AU2016202235 A AU 2016202235A AU 2016202235 A AU2016202235 A AU 2016202235A AU 2016202235 A1 AU2016202235 A1 AU 2016202235A1
- Authority
- AU
- Australia
- Prior art keywords
- cldn6
- claudin
- antibodies specific
- antibodies
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003859 Claudin-6 Human genes 0.000 title 2
- 108090000229 Claudin-6 Proteins 0.000 title 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016202235A AU2016202235B2 (en) | 2009-11-11 | 2016-04-11 | Antibodies specific for Claudin 6 (CLDN6) |
| AU2018201640A AU2018201640B2 (en) | 2009-11-11 | 2018-03-07 | Antibodies specific for Claudin 6 (CLDN6) |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26020209P | 2009-11-11 | 2009-11-11 | |
| EP09014136.7 | 2009-11-11 | ||
| US61/260,202 | 2009-11-11 | ||
| EP09014136A EP2322555A1 (en) | 2009-11-11 | 2009-11-11 | Antibodies specific for claudin 6 (CLDN6) |
| US36161810P | 2010-07-06 | 2010-07-06 | |
| US61/361,618 | 2010-07-06 | ||
| EP10006956.6 | 2010-07-06 | ||
| EP10006956 | 2010-07-06 | ||
| PCT/EP2010/006888 WO2011057788A1 (en) | 2009-11-11 | 2010-11-11 | Antibodies specific for claudin 6 (cldn6) |
| AU2010318316A AU2010318316B2 (en) | 2009-11-11 | 2010-11-11 | Antibodies specific for Claudin 6 (CLDN6) |
| AU2016202235A AU2016202235B2 (en) | 2009-11-11 | 2016-04-11 | Antibodies specific for Claudin 6 (CLDN6) |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010318316A Division AU2010318316B2 (en) | 2009-11-11 | 2010-11-11 | Antibodies specific for Claudin 6 (CLDN6) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018201640A Division AU2018201640B2 (en) | 2009-11-11 | 2018-03-07 | Antibodies specific for Claudin 6 (CLDN6) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016202235A1 true AU2016202235A1 (en) | 2016-05-12 |
| AU2016202235B2 AU2016202235B2 (en) | 2017-12-07 |
Family
ID=43480734
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010318316A Active AU2010318316B2 (en) | 2009-11-11 | 2010-11-11 | Antibodies specific for Claudin 6 (CLDN6) |
| AU2016202235A Active AU2016202235B2 (en) | 2009-11-11 | 2016-04-11 | Antibodies specific for Claudin 6 (CLDN6) |
| AU2018201640A Active AU2018201640B2 (en) | 2009-11-11 | 2018-03-07 | Antibodies specific for Claudin 6 (CLDN6) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010318316A Active AU2010318316B2 (en) | 2009-11-11 | 2010-11-11 | Antibodies specific for Claudin 6 (CLDN6) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018201640A Active AU2018201640B2 (en) | 2009-11-11 | 2018-03-07 | Antibodies specific for Claudin 6 (CLDN6) |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9487584B2 (en) |
| EP (3) | EP3689911A1 (en) |
| JP (3) | JP5889196B2 (en) |
| KR (4) | KR20210130250A (en) |
| CN (4) | CN105348389B (en) |
| AU (3) | AU2010318316B2 (en) |
| BR (1) | BR112012011143B1 (en) |
| CA (2) | CA2775373C (en) |
| CY (2) | CY1120300T1 (en) |
| DK (2) | DK2499161T3 (en) |
| ES (2) | ES2784483T3 (en) |
| HK (1) | HK1253300A1 (en) |
| HR (2) | HRP20171749T1 (en) |
| HU (2) | HUE035516T2 (en) |
| IL (2) | IL218628B (en) |
| LT (2) | LT3305813T (en) |
| ME (1) | ME02943B (en) |
| MX (2) | MX347150B (en) |
| NO (1) | NO2499161T3 (en) |
| NZ (2) | NZ716587A (en) |
| PL (2) | PL3305813T3 (en) |
| PT (2) | PT2499161T (en) |
| RS (2) | RS56502B1 (en) |
| RU (1) | RU2675997C2 (en) |
| SG (2) | SG10202110692WA (en) |
| SI (2) | SI3305813T1 (en) |
| UA (1) | UA117799C2 (en) |
| WO (1) | WO2011057788A1 (en) |
| ZA (1) | ZA201202418B (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (en) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | Bar code reader |
| DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
| PL2398902T3 (en) | 2009-02-20 | 2024-02-26 | Astellas Pharma Inc. | Methods and compositions for diagnosis and treatment of cancer |
| NO2499161T3 (en) | 2009-11-11 | 2018-02-03 | ||
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| AU2012258087B2 (en) * | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
| ES2703936T3 (en) * | 2011-05-13 | 2019-03-13 | Ganymed Pharmaceuticals Gmbh | Antibodies for the treatment of cancer expressing claudin 6 |
| CN103320381B (en) * | 2012-03-23 | 2015-04-15 | 上海市儿童医院 | Pluripotent stem cell surface marker and application thereof |
| PT2888283T (en) | 2012-08-24 | 2018-11-16 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| BR122020024124B1 (en) * | 2012-11-13 | 2024-01-30 | Biontech Ag | AGENTS FOR THE TREATMENT OF CANCEROUS DISEASES EXPRESSING CLAUDIN |
| RU2678127C2 (en) * | 2012-11-13 | 2019-01-23 | Бионтех Аг | Agents for treatment of claudin expressing cancer diseases |
| EP3738612A1 (en) * | 2013-07-31 | 2020-11-18 | Biontech AG | Diagnosis and therapy of cancer involving cancer stem cells |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| SG11201603397QA (en) * | 2013-11-06 | 2016-05-30 | Stemcentrx Inc | Novel anti-claudin antibodies and methods of use |
| JPWO2015068847A1 (en) | 2013-11-11 | 2017-03-09 | 中外製薬株式会社 | Antigen-binding molecules comprising modified antibody variable regions |
| US10370423B2 (en) * | 2014-04-01 | 2019-08-06 | Biotech Cell & Gene thrapies GMBH | Claudin-6-specific immunoreceptors and T cell epitopes |
| MA40921A (en) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | ANTI-GENETIC CHEMERICAL ANTI-CLDN RECEPTORS AND METHODS OF USE |
| TWI740809B (en) | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | Database of antigen-binding molecules containing altered antibody variable regions |
| CN109996544A (en) | 2016-06-27 | 2019-07-09 | 加利福尼亚大学董事会 | Treatment of cancer combination |
| WO2018105560A1 (en) * | 2016-12-07 | 2018-06-14 | 国立大学法人大阪大学 | Claudin 5 ANTIBODY, AND MEDICINE CONTAINING SAID ANTIBODY |
| WO2018207638A1 (en) * | 2017-05-08 | 2018-11-15 | 国立大学法人大阪大学 | Anti-cldn-5 antibody, and drug containing said antibody |
| WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | Antibodies useful in cancer diagnosis |
| EP3690038A4 (en) | 2017-09-29 | 2021-05-19 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2019111871A1 (en) | 2017-12-05 | 2019-06-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137 |
| JP2021510064A (en) * | 2018-01-05 | 2021-04-15 | 中外製薬株式会社 | Cytotoxic Tocyte Therapeutic Agent |
| WO2020075325A1 (en) * | 2018-10-09 | 2020-04-16 | 公立大学法人福島県立医科大学 | Biomarker for predicting prognosis of endometrial cancer patient |
| JP2022521723A (en) | 2019-02-15 | 2022-04-12 | インテグラル・モレキュラー・インコーポレイテッド | Claudin 6 antibody and its use |
| CN113631229A (en) | 2019-03-25 | 2021-11-09 | 第一三共株式会社 | Antibody-pyrrolobenzodiazepine derivative conjugates |
| CA3139250A1 (en) * | 2019-07-10 | 2021-01-14 | Naoki Kimura | Claudin-6 binding molecules and uses thereof |
| CN111087465B (en) * | 2019-12-24 | 2020-12-08 | 广州医科大学 | Antibody coupling drug for claudin 6 and application thereof |
| MX2022012092A (en) | 2020-03-31 | 2022-10-13 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof. |
| WO2022183502A1 (en) * | 2021-03-05 | 2022-09-09 | 上海吉倍生物技术有限公司 | Anti-cldn6 antibody and use thereof |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| JPWO2023053282A1 (en) | 2021-09-29 | 2023-04-06 | ||
| WO2024022512A1 (en) * | 2022-07-29 | 2024-02-01 | Nanjing Legend Biotech Co., Ltd. | Claudin-6 binding moieties and uses thereof |
| CN116064622B (en) * | 2023-02-13 | 2023-10-13 | 优睿赛思(武汉)生物科技有限公司 | Preparation and application of Claudin6-mCherry reporter gene CHO-K1 stable transgenic cell strain |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
| WO2002008288A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| NZ510464A (en) | 1998-09-01 | 2004-05-28 | Genentech Inc | Further pro polypeptides and sequences thereof |
| EP1127119A1 (en) | 1998-11-03 | 2001-08-29 | Adherex Technologies, Inc. | Compounds and methods for modulating claudin-mediated functions |
| EP1140970A4 (en) | 1998-12-17 | 2003-10-22 | Human Genome Sciences Inc | 47 human secreted proteins |
| AU3479700A (en) | 1999-02-22 | 2000-09-14 | Incyte Pharmaceuticals, Inc. | Genes associated with diseases of the colon |
| EP1185648B1 (en) | 1999-06-02 | 2007-03-21 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| KR20080075044A (en) * | 1999-07-12 | 2008-08-13 | 제넨테크, 인크. | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| CA2402563A1 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2001051513A2 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Ovarian tumor-associated sequences |
| NZ553687A (en) | 2000-03-30 | 2010-03-26 | Whitehead Biomedical Inst | RNA sequence-specific mediators of RNA interference |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2001271973A1 (en) | 2000-07-20 | 2002-02-05 | Kevin P. Baker | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
| PT1354034E (en) | 2000-11-30 | 2008-02-28 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| DE60233509D1 (en) * | 2001-06-20 | 2009-10-08 | Fibron Ltd | FGFR3 BLOCKING ANTIBODIES, METHOD OF SCREENING THEREOF AND USES THEREOF |
| KR100628425B1 (en) | 2001-06-20 | 2006-09-28 | 제넨테크, 인크. | Compositions and Methods for the Diagnosis and Treatment of Tumor |
| CA2379661A1 (en) * | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
| EP1571968A4 (en) | 2002-04-16 | 2007-10-17 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| CA2500687A1 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| DK1558648T3 (en) | 2002-10-17 | 2012-04-23 | Genmab As | HUMAN MONOCLONAL ANTIBODIES AGAINST CD20 |
| EP1578996A4 (en) | 2002-10-18 | 2007-12-19 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| AT500651B9 (en) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | ACTIVE IMMUNIZING ANTIBODY |
| KR20060031809A (en) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Compositions and methods for treating and diagnosing cancer |
| US20080305493A1 (en) | 2004-03-08 | 2008-12-11 | Avalon Pharmaceuticals | Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| ITRM20050297A1 (en) * | 2005-06-08 | 2006-12-09 | Univ Siena | ANTIBODIES DIRECTED AGAINST MYELINE BASIC PROTEIN WHICH RECOGNIZE AN EPITOPE OF CD64 AND THE USE OF THEM AS IMMUNODEPRESSIVE. |
| SG2014010029A (en) * | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| PT2066351E (en) * | 2006-10-02 | 2015-11-30 | Squibb & Sons Llc | Human antibodies that bind cxcr4 and uses thereof |
| CA2668484A1 (en) * | 2006-11-13 | 2008-05-22 | F. Hoffmann-La Roche Ag | Cancerous disease modifying antibodies 180706-02 |
| JPWO2008114733A1 (en) * | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | Anti-Claudin-4 antibody |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2009025759A1 (en) | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| WO2009028663A1 (en) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | Anti-claudin-3 antibody |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| BRPI0907237A2 (en) * | 2008-01-11 | 2015-07-14 | Univ Tokyo | Anti-cldn6 antibody |
| EP2285392A4 (en) | 2008-04-11 | 2012-06-06 | Bionovo Inc | Anticancer methods employing extracts of gleditsia sinensis lam |
| US9005963B2 (en) | 2008-10-14 | 2015-04-14 | Ablynx N.V. | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| DE102009026966A1 (en) | 2008-12-18 | 2010-07-01 | Robert Bosch Gmbh | Operation of a brake booster as a pedal simulator |
| EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| PL2398902T3 (en) | 2009-02-20 | 2024-02-26 | Astellas Pharma Inc. | Methods and compositions for diagnosis and treatment of cancer |
| EP2322555A1 (en) | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| NO2499161T3 (en) * | 2009-11-11 | 2018-02-03 | ||
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| AU2012258087B2 (en) | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
| EP2605017A1 (en) | 2011-12-16 | 2013-06-19 | Protagen AG | Marker sequences for gynaecological malignoma and use of same |
| CA2878400A1 (en) | 2012-07-19 | 2014-01-23 | Amgen Inc. | Btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| RU2678127C2 (en) * | 2012-11-13 | 2019-01-23 | Бионтех Аг | Agents for treatment of claudin expressing cancer diseases |
| US10370423B2 (en) * | 2014-04-01 | 2019-08-06 | Biotech Cell & Gene thrapies GMBH | Claudin-6-specific immunoreceptors and T cell epitopes |
-
2010
- 2010-11-11 NO NO10778877A patent/NO2499161T3/no unknown
- 2010-11-11 LT LTEP17189247.4T patent/LT3305813T/en unknown
- 2010-11-11 ES ES17189247T patent/ES2784483T3/en active Active
- 2010-11-11 PT PT107788770T patent/PT2499161T/en unknown
- 2010-11-11 CA CA2775373A patent/CA2775373C/en active Active
- 2010-11-11 DK DK10778877.0T patent/DK2499161T3/en active
- 2010-11-11 CN CN201510347761.9A patent/CN105348389B/en active Active
- 2010-11-11 CN CN202010370074.XA patent/CN111875703B/en active Active
- 2010-11-11 CA CA3050655A patent/CA3050655A1/en active Pending
- 2010-11-11 ME MEP-2017-261A patent/ME02943B/en unknown
- 2010-11-11 PL PL17189247T patent/PL3305813T3/en unknown
- 2010-11-11 JP JP2012538239A patent/JP5889196B2/en active Active
- 2010-11-11 NZ NZ716587A patent/NZ716587A/en unknown
- 2010-11-11 SI SI201031999T patent/SI3305813T1/en unknown
- 2010-11-11 SG SG10202110692WA patent/SG10202110692WA/en unknown
- 2010-11-11 DK DK17189247.4T patent/DK3305813T3/en active
- 2010-11-11 RU RU2012123995A patent/RU2675997C2/en active
- 2010-11-11 KR KR1020217033643A patent/KR20210130250A/en not_active IP Right Cessation
- 2010-11-11 SI SI201031568T patent/SI2499161T1/en unknown
- 2010-11-11 BR BR112012011143A patent/BR112012011143B1/en active IP Right Grant
- 2010-11-11 MX MX2012005444A patent/MX347150B/en active IP Right Grant
- 2010-11-11 PT PT171892474T patent/PT3305813T/en unknown
- 2010-11-11 SG SG10201500975YA patent/SG10201500975YA/en unknown
- 2010-11-11 CN CN201610429065.7A patent/CN106432500B/en active Active
- 2010-11-11 AU AU2010318316A patent/AU2010318316B2/en active Active
- 2010-11-11 EP EP20151560.8A patent/EP3689911A1/en active Pending
- 2010-11-11 WO PCT/EP2010/006888 patent/WO2011057788A1/en active Application Filing
- 2010-11-11 HU HUE10778877A patent/HUE035516T2/en unknown
- 2010-11-11 EP EP10778877.0A patent/EP2499161B8/en active Active
- 2010-11-11 US US13/503,461 patent/US9487584B2/en active Active
- 2010-11-11 LT LTEP10778877.0T patent/LT2499161T/en unknown
- 2010-11-11 NZ NZ734307A patent/NZ734307A/en unknown
- 2010-11-11 UA UAA201207057A patent/UA117799C2/en unknown
- 2010-11-11 ES ES10778877.0T patent/ES2649389T3/en active Active
- 2010-11-11 RS RS20171131A patent/RS56502B1/en unknown
- 2010-11-11 KR KR1020207017665A patent/KR102317098B1/en active IP Right Grant
- 2010-11-11 EP EP17189247.4A patent/EP3305813B1/en active Active
- 2010-11-11 PL PL10778877T patent/PL2499161T3/en unknown
- 2010-11-11 KR KR1020127012326A patent/KR101960509B1/en active IP Right Grant
- 2010-11-11 HU HUE17189247A patent/HUE049404T2/en unknown
- 2010-11-11 CN CN201080051324.8A patent/CN102741289B/en active Active
- 2010-11-11 KR KR1020197007436A patent/KR102126964B1/en active IP Right Grant
- 2010-11-11 RS RS20200427A patent/RS60168B1/en unknown
-
2012
- 2012-03-14 IL IL218628A patent/IL218628B/en active IP Right Grant
- 2012-04-03 ZA ZA2012/02418A patent/ZA201202418B/en unknown
- 2012-05-09 MX MX2020011790A patent/MX2020011790A/en unknown
-
2015
- 2015-12-18 JP JP2015247222A patent/JP6125604B2/en active Active
-
2016
- 2016-04-11 AU AU2016202235A patent/AU2016202235B2/en active Active
- 2016-04-20 US US15/133,783 patent/US9932401B2/en active Active
- 2016-07-11 IL IL246710A patent/IL246710B/en active IP Right Grant
-
2017
- 2017-04-05 JP JP2017075017A patent/JP6502992B2/en active Active
- 2017-11-14 HR HRP20171749TT patent/HRP20171749T1/en unknown
- 2017-11-27 CY CY20171101246T patent/CY1120300T1/en unknown
-
2018
- 2018-01-31 US US15/885,454 patent/US10745477B2/en active Active
- 2018-03-07 AU AU2018201640A patent/AU2018201640B2/en active Active
- 2018-10-02 HK HK18112592.7A patent/HK1253300A1/en unknown
-
2020
- 2020-04-14 HR HRP20200591TT patent/HRP20200591T1/en unknown
- 2020-04-15 CY CY20201100363T patent/CY1123192T1/en unknown
- 2020-07-07 US US16/922,179 patent/US11858988B2/en active Active
-
2023
- 2023-11-27 US US18/520,242 patent/US20240092896A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253300A1 (en) | Antibodies specific for claudin 6 (cldn6) | |
| AU2016202235A1 (en) | Antibodies specific for Claudin 6 (CLDN6) | |
| AU2013207589A1 (en) | Anti-Siglec-15 Antibody | |
| GB0708002D0 (en) | Antibodies | |
| SI2200700T1 (en) | Novel antibodies | |
| EP2321720A4 (en) | State separation for application changes | |
| WO2010080124A9 (en) | Nkg2d-fc for immunotherapy | |
| GB0702888D0 (en) | Novel Antibodies | |
| GB0718737D0 (en) | Antibodies | |
| EP2114996B8 (en) | Method for preparing hypoallergens | |
| AU2006904752A0 (en) | Uses for Antibodies | |
| AU2007900058A0 (en) | Recombinant Antibodies | |
| AU2008906056A0 (en) | Coupling for pusher tug | |
| AU2008903401A0 (en) | Anti-C5L2 monoclonal antibodies | |
| AU2008905475A0 (en) | Interchange hopper system | |
| AU2008903816A0 (en) | Solid antigens | |
| AU2007902751A0 (en) | Neutralizing antibodies | |
| AU2007903088A0 (en) | Modified Colostrum | |
| GB0724185D0 (en) | Antibodies | |
| AU2008902193A0 (en) | Separation process | |
| AU2008900025A0 (en) | Separation apparatus | |
| AU2007907019A0 (en) | Breasts for you | |
| AU2009900416A0 (en) | Interchange hopper system | |
| AU2008902940A0 (en) | Gas-solid separation apparatus | |
| AU2007900272A0 (en) | Improved Process |